ABL Bio Inc (298380) — Strategic Asset Allocation Index
ABL Bio Inc (298380) has a Strategic Asset Allocation Index of 66.5% as of March 2025. Strategic assets (PP&E of ₩95.17 Billion plus long-term investments of ₩-) total ₩95.17 Billion, measured against net assets of ₩143.03 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
ABL Bio Inc Strategic Asset Allocation Index (2018–2024)
This chart shows how ABL Bio Inc's Strategic Asset Allocation Index has evolved across 7 annual periods from 2018 to 2024. As of March 2025, the index stands at 66.5%, representing strategic assets of ₩95.17 Billion against net assets of ₩143.03 Billion KRW. Explore 298380 cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for ABL Bio Inc (2018–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for ABL Bio Inc from 2018 to 2024, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 298380 market cap.
| Year | SAAI | Strategic Assets (KRW) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 51.1% | ₩85.41 Billion | ₩85.41 Billion | ₩- | ₩167.28 Billion | ▼ -51.6 pp |
| 2023 | 102.6% | ₩76.03 Billion | ₩76.03 Billion | ₩- | ₩74.08 Billion | ▲ +93.0 pp |
| 2022 | 9.7% | ₩6.71 Billion | ₩6.71 Billion | ₩- | ₩69.51 Billion | ▲ +3.8 pp |
| 2021 | 5.9% | ₩3.30 Billion | ₩3.30 Billion | ₩- | ₩55.95 Billion | ▲ +1.4 pp |
| 2020 | 4.5% | ₩4.07 Billion | ₩4.07 Billion | ₩- | ₩90.66 Billion | ▲ +0.7 pp |
| 2019 | 3.8% | ₩5.04 Billion | ₩5.04 Billion | ₩- | ₩132.01 Billion | ▼ -0.7 pp |
| 2018 | 4.5% | ₩7.07 Billion | ₩2.70 Billion | ₩4.37 Billion | ₩156.96 Billion | — |